Gufic BioSciences Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 13 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.0K Cr
Gufic Biosciences expects a consistent revenue growth of around 15% year-over-year. Revenue is expected to grow at a minimum of 15% year-over-year, driven by both domestic and international markets.
From Gufic BioSciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹432
Market Cap
₹4.0K Cr
P/E Ratio
62.6
Revenue Rank
Margin Rank
How does Gufic BioSciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Gufic BioSciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Gufic BioSciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹231 Cr, net profit ₹12 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Gufic Biosciences expects a consistent revenue growth of around 15% year-over-year.
- →Domestic market growth driven by new product launches in critical care, IVF, botulinum toxin, orthopedics, gynecology, and pain management.
- →International business growth fueled by marketing authorizations in Europe, South Africa, Canada, Brazil, and others, expanding both tender and private markets.
- →Shift towards holding marketing authorizations internationally to improve margins and control.
- →CMO business expected to grow modestly, with GLP-1 orders peaking soon; overall CMO share around 15%-18%.
- →Backward integration and new molecule additions expected to enhance margins and stability.
- →Indore plant utilization at 30% with EBITDA breakeven, scaling up for higher contributions.
- →Overall optimism to reap benefits of past investments in the next 2-4 years with expanded product portfolio and geographic reach.
📈 Profitability & Margins
Rank 2- →Revenue is expected to grow at a minimum of 15% year-over-year, driven by both domestic and international markets.
- →EBITDA margin projected to improve from 16.26% in FY26 to around 18% in FY27, with a potential to exceed 20% by 2030.
- →Gross margin is anticipated to expand by 0.5% to 1% annually, fueled by product mix, geographic diversification, and pricing.
- →Operating leverage benefits expected with Indore plant scaling up, now at breakeven with 30% utilization.
- →Investments in dossier filings and marketing authorization in international markets, including Europe and other private markets, to support margin expansion.
- →Profit after tax (PAT) declined in FY26 but expected to improve with margin expansion and revenue growth.
- →Cash flow from operations expected to strengthen, with conversion ratios improving as business scales.
- →Overall, Gufic aims for steady margin and earnings growth with continued expansion of higher-margin domestic and international businesses.
🏗️ Capital Expenditure Plans
Yes- →No major new greenfield capex is planned for the next 2 to 3 years; focus is on maintenance/replacement capex.
- →Navsari facility will have annual replacement capex of around INR 20 crores to maintain operations.
- →Investments have been made in Indore expansion and dossier/regulatory work, mostly completed.
- →Clinical trial investments ongoing, e.g., INR 40-50 crores for a long-acting product and INR 15-20 crores for short-acting clinical trials, funded through internal cash flows without incurring new debt.
- →Strategic new projects may arise but no large-scale capex is foreseen in near term.
- →Efforts continue in R&D, with 8-10% of annual revenue reinvested for IP and product development.
- →Overall, future capex mainly for replacement and minor strategic purposes, avoiding debt escalation.
💰 Fundraising & Capital Structure
Yes- →No new greenfield capex is planned in the next 2 years, indicating no immediate large fundraising needs for expansion capex.
- →Existing short-term debt levels (~INR 400 crores gross debt) are expected to suffice for working capital needs over the next 2 to 3 years.
- →Long-term debt has been reducing year-over-year, with no indication of new long-term debt planned except for possible replacement capex.
- →Cash and cash equivalents have been increasing (INR 75 crores as of March 2026), but debt levels are expected to remain stable at current levels.
- →Investments such as INR 6.5 crores in Saraswat Bank reflect strategic bank relationships, not fundraising requirements.
- →Overall, the company expects debt levels to remain around INR 400 crores without new significant debt or equity fundraising in the near term.
📋 Order Book & Pipeline
No information- →The transcript does not explicitly mention specific current or expected order book or pending orders by value or volume.
- →Management discusses ongoing efforts in gaining marketing authorizations internationally and recruitment in international markets to support front-end business.
- →There is reference to batches planned for U.S. FDA filings and inspections anticipated by the end of the year to initiate U.S. market operations around 2028-29.
- →Expansion in various geographies (Europe, U.S., South Africa, Canada, Brazil) is expected to add incremental business with more molecules being introduced year-over-year.
- →CMO business sees short-term growth from GLP-1 related orders, but expected to saturate after 1-2 years.
- →Overall growth driven by domestic new product launches and international market expansion rather than specific large pending orders.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Gufic BioSciences Ltd Q4 FY26 results?
Gufic Biosciences expects a consistent revenue growth of around 15% year-over-year. Revenue is expected to grow at a minimum of 15% year-over-year, driven by both domestic and international markets.
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 62.6 with a market cap of ₹3,955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
No major new greenfield capex is planned for the next 2 to 3 years; focus is on maintenance/replacement capex.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.